Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
Collaborative Drug Discovery (CDD) announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).
BIA calls for coordinated action and a clear mandate for Health Data Research Service (HDRS) to prioritise UK value creation with health innovators and job creators, a key sector for economic growth
BIA’s health data vision 2035 report sets out how the UK can use consented and well-governed health data to drive economic growth, innovation and better patient outcomes.
PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.
It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.
ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.
The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
